COMMUNIQUÉS West-GlobeNewswire

-
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
21/10/2025 -
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
21/10/2025 -
Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor
21/10/2025 -
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
21/10/2025 -
PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes
21/10/2025 -
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
21/10/2025 -
Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance
21/10/2025 -
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
21/10/2025 -
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
21/10/2025 -
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
21/10/2025 -
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
20/10/2025 -
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
20/10/2025 -
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
20/10/2025 -
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
20/10/2025 -
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
20/10/2025 -
BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
20/10/2025 -
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
20/10/2025 -
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
20/10/2025 -
Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 2025
20/10/2025
Pages